Share-based Payment Arrangement, Expense in USD of AbCellera Biologics Inc. from 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
AbCellera Biologics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2019 to Q3 2025.
  • AbCellera Biologics Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $13.9M, a 19.1% decline year-over-year.
  • AbCellera Biologics Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $58.1M, a 15.5% decline year-over-year.
  • AbCellera Biologics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $67.6M, a 5.29% increase from 2023.
  • AbCellera Biologics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $64.2M, a 29.7% increase from 2022.
  • AbCellera Biologics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $49.5M, a 61.5% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

AbCellera Biologics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $58.1M $13.9M -$3.27M -19.1% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-06
Q2 2025 $61.4M $14.2M -$3.57M -20.1% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 $65M $14.8M -$2.62M -15.1% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q4 2024 $67.6M $15.2M -$1.22M -7.44% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-27
Q3 2024 $68.8M $17.2M +$1.3M +8.21% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-06
Q2 2024 $67.5M $17.8M +$1.38M +8.43% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 $66.1M $17.4M +$1.94M +12.5% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q4 2023 $64.2M $16.4M +$3.13M +23.5% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-27
Q3 2023 $61.1M $15.9M +$4.11M +35% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-04
Q2 2023 $57M $16.4M +$4.29M +35.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $52.7M $15.5M +$3.18M +25.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $49.5M $13.3M +$4.28M +47.4% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-27
Q3 2022 $45.2M $11.8M +$4.05M +52.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $41.2M $12.1M +$3.64M +43% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $37.5M $12.3M +$6.86M +126% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $30.6M $9.04M +$4.42M +95.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 $26.2M $7.71M +$5.77M +299% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $20.5M $8.47M +$7.87M +1298% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $12.6M $5.43M +$4.19M +339% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $8.4M $4.62M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-21
Q3 2020 $1.93M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $606K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 $1.24M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14

AbCellera Biologics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $67.6M +$3.4M +5.29% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 $64.2M +$14.7M +29.7% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 $49.5M +$18.8M +61.5% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-27
2021 $30.6M +$22.2M +265% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-20
2020 $8.4M +$7.51M +843% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
2019 $890K Jan 1, 2019 Dec 31, 2019 10-K 2022-02-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.